(Q44810202)

6 December 2017

title

Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial (English)

1 reference

6 December 2017

main subject

phase II clinical trial

0 references

0 references

4

Ayalew Tefferi

1 reference

6 December 2017

3

Antje Hoering

1 reference

6 December 2017

10

Steven R Alberts

1 reference

6 December 2017

author name string

Alvaro Moreno-Aspitia

1

1 reference

6 December 2017

Gerardo Colon-Otero

2

1 reference

6 December 2017

Robert D Niedringhaus

5

1 reference

6 December 2017

Allen Vukov

6

1 reference

6 December 2017

Chin-Yang Li

7

1 reference

6 December 2017

David M Menke

8

1 reference

6 December 2017

Susan M Geyer

9

1 reference

6 December 2017

North Central Cancer Treatment Group

11

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

6 December 2017

1 reference

6 December 2017

volume

107

1 reference

6 December 2017

issue

4

1 reference

6 December 2017

page(s)

767-772

1 reference

Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Etiopathogeny, prognosis and therapy of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Karyotypic analysis in primary myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Molecular features of primary MDS with cytogenetic changes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Clonal lymphocytes are detectable in only some cases of MDS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

T cell‐mediated inhibition of erythropoiesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22047

7 January 2021

Identifiers

DOI

10.1002/CNCR.22047

1 reference

6 December 2017

1 reference